New blood test for ovarian cancer screening
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study uses a special blood test (SERS) to find tiny signs of ovarian cancer in the blood. It may help diagnose ovarian cancer earlier or more accurately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have ovarian cancer (any type, newly diagnosed) or you are having surgery for a non-cancer condition
- You can give a blood sample for the test
- You do not have another type of cancer or a serious infection
- You are not pregnant, breastfeeding, or planning pregnancy during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new blood test to help find ovarian cancer early in women who are at average risk. By joining, you may help improve early detection, which could lead to better outcomes.
This study is testing new blood tests that might help detect ovarian cancer earlier by looking for specific markers. It involves people with suspected ovarian cancer and healthy volunteers, and aims to improve how we diagnose the disease.
This trial tests a new blood test (OCS) that may help detect if ovarian cancer comes back after initial treatment. It is for people whose CA125 levels were normal at diagnosis.
This study is testing a blood test to see if it can catch ovarian cancer early. You may be eligible if you have been recently diagnosed with ovarian cancer and haven't started treatment yet.
This study checks whether a blood test (ctDNA) can show how well ovarian, fallopian tube, or primary peritoneal cancer treatment is working. If the test reliably reflects response, it could help doctors adjust treatment earlier and more precisely.
This study looks at “biomarkers,” meaning measurable signals in blood and tumor tissue, in people with advanced ovarian-type cancers. The goal is to understand these markers and how they relate to the cancer, which may help guide future care.
Hear when a new Ovarian Cancer, Epithelial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.